JGJohannes Gnörich

Johannes Gnörich

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Johannes Gnörich has a total of 329 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cladribine Treatment in a Retrospective Case Series in GAD65-Antibody–Associated Temporal Lobe Epilepsy

    by Franziska S. Thaler, Jan Bartosch, Ingrid Meinl, Julia S. Dorneich, Marianthi Zeinaki, Johannes Gnörich, Dario Dhoqina, Elisabeth Kaufmann, Jan Rémi, Martin Kerschensteiner, et al.

    Background and ObjectivesPatients with GAD65-antibody–associated autoimmune encephalitis presenting with temporal lobe epilepsy (TLE) respond poorly to treatment, resulting in persistent seizures a...

  • Open Access

    Spatial multi-omics identifies early synaptic pruning and context-specific dopaminergic vulnerability in synucleinopathies

    by Svenja-Lotta Rumpf, Felix L. Strübing, Karsten Nalbach, Claudia Marina Vargiu, Giacomo Berg, Stefan F. Lichtenthaler, Piero Parchi, Pan Gao, Weilin Chen, Matthias Brendel, et al.

    Parkinson’s disease (PD) is characterized by degeneration of dopaminergic neurons in the substantia nigra pars compacta, but the molecular events preceding neuronal loss remain unclear. Here, we combine spatial transcriptomics, spatial proteomics, and α-synuclein (αSyn) seed amplification assays to profile post-mortem midbrain tissue from controls, incidental Lewy body disease (iLBD), PD, Alzheimer’s disease (AD), and AD with Lewy body pathology (AD + LBP). We find that αSyn seeding activity correlates with dopaminergic neuron loss in PD-spectrum cases but not in AD-associated LBP, indicating disease-context dependent relationships between αSyn pathology and neurodegeneration. In iLBD, before overt substantia nigra Lewy pathology or detectable αSyn aggregation, we detect increased expression of the complement component C1QC together with loss of inhibitory synaptic markers. These findings support early complement-associated remodeling of inhibitory synapses as a potential pathogenic event preceding overt αSyn aggregation and neuronal degeneration in PD.

  • Open Access

    Tracking of Neuroinflammation Dynamics During Combined Anti-β-Amyloid Therapy (AAT) and Immunomodulation in a Preclinical Alzheimer’s Disease Model

    by Karin Wind-Mark, Lea H. Kunze, Michael Willem, Giovanna Palumbo, Camilla Giudici, Brigitte Nuscher, Guido Boening, Franz J. Gildehaus, Simon Lindner, Rudolf A. Werner, et al.

    Neuroinflammation is increasingly recognized as a key modulator of therapeutic response and adverse events in Alzheimer’s disease (AD), especially during anti-amyloid-β (Aβ) monoclonal antibody (Aβ-mAb) treatment. We applied longitudinal translocator protein (TSPO) positron emission tomography (PET) to evaluate TSPO-associated neuroinflammatory responses to chronic Aβ-mAb therapy and their modulation by the peroxisome proliferator-activated receptor γ (PPARγ) agonist pioglitazone. AppNL-G-F knock-in mice underwent TSPO-PET and Aβ-PET imaging at 5, 7.5, and 10 months of age across four treatment arms: placebo, Aβ-mAb, pioglitazone, and combination therapy. TSPO-PET detected early and progressive neuroinflammatory responses to Aβ-mAb that appeared lower with pioglitazone co-treatment. Both mono- and combination therapy were associated with altered temporal and spatial dynamics of the TSPO-PET signal. In addition, we applied a previously validated microglia desynchronization index based on TSPO-PET connectivity, which captured individual variation in regional TSPO-PET organization and correlated with cognitive performance. Together, TSPO-PET and its regional synchronicity can quantify longitudinal, region-specific treatment effects, which may help differentiate harmful from adaptive neuroinflammatory responses. These findings highlight the potential of TSPO-PET as a stratification biomarker to optimize therapeutic interventions. TSPO-PET therefore enables in vivo tracking of treatment-associated neuroinflammatory responses during anti-Aβ immunotherapy and provides a non-invasive framework for evaluating combination strategies targeting amyloid pathology and immune regulation in AD.

  • Open Access

    Tracking of Neuroinflammation Dynamics During Combined Anti-β-Amyloid Therapy (AAT) and Immunomodulation in a Preclinical Alzheimer’s Disease Model

    by Karin Wind-Mark, Lea H. Kunze, Michael Willem, Giovanna Palumbo, Camilla Giudici, Brigitte Nuscher, Guido Boening, Franz J. Gildehaus, Simon Lindner, Rudolf A. Werner, et al.

    Neuroinflammation is increasingly recognized as a key modulator of therapeutic response and adverse events in Alzheimer’s disease (AD), especially during anti-amyloid-β (Aβ) monoclonal antibody (Aβ-mAb) treatment. We applied longitudinal translocator protein (TSPO) positron emission tomography (PET) to evaluate microglial activation in response to chronic Aβ-mAb therapy and its modulation by the PPAR-γ agonist pioglitazone. AppNL-G-F knock-in mice underwent TSPO-PET and Aβ-PET imaging at 5, 7.5, and 10 months of age across four treatment arms: placebo, Aβ-mAb, pioglitazone, and combination therapy. TSPO-PET detected early and progressive neuroinflammatory responses to Aβ-mAb that were attenuated by pioglitazone co-treatment. Both mono- and combination therapy modulated the temporal and spatial dynamics of the TSPO-PET signal. In addition, we derived a microglial desynchronization index from TSPO-PET connectivity, which captured individual neuroimmune responses and correlated with cognitive performance. Together, TSPO-PET and its regional synchronicity can quantify longitudinal, region-specific treatment effects, which may help to differentiate harmful from adaptive neuroinflammatory responses. These findings highlight the potential of TSPO-PET as a stratification biomarker to optimize therapeutic interventions. In summary, TSPO-PET enables in vivo tracking of treatment-associated neuroinflammatory responses during anti-Aβ immunotherapy and provides a non-invasive framework for evaluating combination strategies targeting amyloid pathology and immune regulation in AD.

    • 2 April 2026
      • Vol. 67  (6) , 974-980
    Open Access

    Detection of Focal Lesions in Epilepsy with [18F]UCB-H Synaptic Vesicle Protein 2A PET Imaging.

    by Vanessa Pakula, Julia S Dorneich, Lukas Frontzkowski, Laura M Bartos, Nicholas Fearns, Sebastian N Roemer-Cassiano, Simon Lindner, Andreas Zwergal, Elisabeth Kaufmann, Günter Höglinger, et al.

    Synaptic vesicle protein 2A (SV2A) is a universal marker of synaptic density. Recent advances in SV2A-targeted radiotracers have opened new windows into synaptic imaging. In focal epilepsy, synaptic dysfunction is a central pathologic feature. Unlike [18F]FDG PET, which reflects neuronal metabolism only indirectly, SV2A PET allows for direct quantification of synaptic density. We therefore evaluated [18F]UCB-H SV2A PET in comparison to [18F]FDG PET in patients with pharmacoresistant, unilateral focal epilepsy, aiming to assess its complementary value to established metabolic imaging. Methods: In total, 29 patients with unilateral focal epilepsy underwent both dynamic [18F]UCB-H PET (0-60 min) and static [18F]FDG PET (30-50 min) imaging. Eight patients were treated with the SV2A-binding medications levetiracetam or brivaracetam. [18F]UCB-H PET time-activity curves were extracted from 35 frames across cortical and subcortical regions, and Pearson correlation coefficients with [18F]FDG uptake were calculated for each frame to identify the most suitable imaging windows. Voxelwise percentage differences between epileptogenic and contralateral healthy hemispheres were computed to determine lesion severity and volume. Finally, we evaluated gaussian smoothing kernels for minimizing background noise while preserving contrast during lesion detection. Results: Treatment with SV2A-binding medications reduced late-phase [18F]UCB-H binding up to 75% compared with untreated individuals, demonstrating high target specificity. Framewise correlation analysis in unaffected contralateral hemispheres revealed significant associations between [18F]UCB-H and [18F]FDG uptake within the 0-10-min and 30-60-min postinjection intervals. These time windows were therefore selected for early- and late-phase analyses, respectively. Within epileptogenic foci, SV2A PET lesion severity correlated with [18F]FDG uptake for both early-phase (r = 0.61, P = 0.0042) and late-phase (r = 0.63, P = 0.0027) imaging. However, only early-phase SV2A PET lesion volume correlated with [18F]FDG lesion volume (r = 0.70, P = 0.0004), whereas late-phase SV2A PET volume did not. In line, [18F]FDG and early-phase [18F]UCB-H PET visually showed broad hypometabolic and hypoperfused areas around the epileptogenic zone, whereas late-phase [18F]UCB-H PET yielded sharper, high-contrast delineation of synaptic abnormalities. Conclusion: Dual-phase [18F]UCB-H PET provides complementary perfusion-like and synaptic information in focal epilepsy and shows spatial correspondence with [18F]FDG PET while offering more spatially confined synaptic signal changes.

  • Open Access

    Assessment of early-phase [ 18 F]florbetaben images as a proxy for brain metabolism in mouse models of Alzheimer’s disease

    by Robin Gröger, Amelie L Englert, Manvir Lalia, Lis de Weerd, Matteo Rovere, Lea Kunze, Giovanna Palumbo, Karin Wind-Mark, Sonja Fixemer, Sebastian N Roemer-Cassiano, et al.

    [ 18 F]FDG–PET and β-amyloid-PET are established tools for assessing biomarker status in Alzheimer’s disease. In this study, we evaluated the potential of early-phase [ 18 F]florbetaben (FBB) PET as a functional proxy for [ 18 F]FDG–PET in preclinical Alzheimer’s disease models by examining regional perfusion and glucose metabolism in two transgenic mouse lines. Ninety-two APPPS1 ( n = 17), APP SAA ( n = 56), and age- and sex-matched wild-type mice ( n = 19; 3–12 months, 40% female) underwent static [ 18 F]FDG–PET (30–60 min p.i.) and dynamic [ 18 F]FBB–PET (0–60 min p.i.). Standardized uptake values were derived for both [ 18 F]FDG–PET and [ 18 F]FBB–PET for the whole brain and 14 Ma–Benveniste–Mirrione atlas regions. We identified the 1–3 min p.i. time window as optimal, yielding the highest concordance with [ 18 F]FDG ( R = 0.53, p < 0.0001) across all regions. Both APPPS1 and APP SAA mice exhibited significant increases in perfusion (both p < 0.0001) and glucose metabolism (APPPS1: p = 0.0028; APP SAA : p < 0.0001) compared to wild-type controls. These findings demonstrate that early-phase [ 18 F]FBB–PET not only mirrors [ 18 F]FDG–PET-derived metabolic changes but also enables a single-scan assessment of β-amyloid pathology and brain function, thereby reducing the number of required scans and potentially the number of animals per study, and strengthening the translational value of preclinical PET research.

  • Case 53: Second Generation Tau-PET in a Case with Arteriovenous Malformation and Mild Cognitive Impairment

    by Johannes Gnörich, Alexander Bernhardt, Elisabeth Wlasich, Julia Kustermann, Hannah Eyob, Katharina Probst, Thomas Liebig, Günter Höglinger, Johannes Levin, Matthias Brendel

  • Case 5: Double Plot Twist in a Patient with a Suspected Diagnosis of Alzheimer’s Disease

    by Johannes Gnörich, Lena Marth, Anna Stockbauer, Elisabeth Wlasich, Julia Kustermann, Pieter Giesbertz, Günter Höglinger, Johannes Levin, Matthias Brendel

  • Open Access

    Spatial Multi-Omics Identifies Early Synaptic Pruning and Context-Specific Dopaminergic Vulnerability in Synucleinopathies

    by Svenja-Lotta Rumpf, Felix Strübing, Karsten Nalbach, Claudia Marina Vargiu, Stefan F. Lichtenthaler, Piero Parchi, Pan Gao, Weilin Chen, Giacomo Berg, Matthias Brendel, et al.

    The molecular events that precede overt neurodegeneration in Parkinson’s disease (PD) remain poorly defined. Incidental Lewy body disease (iLBD)—a prodromal state marked by brainstem-predominant Lewy pathology in the absence of clinical symptoms—offers a unique window into early pathogenesis. Here, we applied a multi-omic spatial profiling approach, integrating transcriptomics, proteomics, and α-synuclein seed amplification assays (SAA), to post-mortem midbrain tissue from neurologically unaffected individuals, iLBD cases, and patients with PD. We identified early and spatially distinct molecular alterations in the substantia nigra pars compacta (SNpc) of iLBD cases, including a marked upregulation of the microglial synaptic pruning factor C1QC. These changes emerged independently of overt Lewy pathology or detectable misfolded α-synuclein, as assessed by SAA or proximity ligation assay (PLA), and were preferentially enriched at GABAergic synapses—highlighting the early vulnerability of inhibitory circuits. Notably, these alterations were absent in Alzheimer’s disease cases with comorbid SNpc Lewy pathology, suggesting that α-synuclein aggregation alone is insufficient to trigger SNpc remodeling. Our findings implicate microglia-mediated synaptic dysfunction as an early, preclinical feature of PD and nominate this mechanism as a potential therapeutic target for halting disease progression before the onset of neurodegeneration. *Svenja-Lotta Rumpf & Felix Strübing contributed equally to this work.

  • SV2A-PET imaging uncovers cortical synapse loss in multiple sclerosis

    by Emily M. Ullrich Gavilanes, Laura M. Bartos, Jonathan A. Gernert, Carla Ares Carral, Diego Ruiz Navarro, Joachim Havla, Lisa-Ann Gerdes, Johannes S. Gnörich, Lea H. Kunze, Julia S. Dorneich, et al.

    Gray matter pathology, including the formation of cortical lesions, predicts progression in people with multiple sclerosis (PwMS). Here, we investigated whether positron emission tomography (PET) imaging using the synaptic vesicle protein 2A (SV2A)–targeting radioligand [ 18 F]UCB-H could help to detect and monitor synapse loss, an early feature of gray matter pathology in MS. First, we confirmed that SV2A is a suitable marker of synapse density in MS by analyzing SV2A mRNA and protein expression in cortical gray matter. We then used a mouse model of cortical MS pathology to demonstrate that SV2A-PET imaging can detect synapse loss in cortical lesions and that synapse densities measured by PET imaging correspond to the densities of genetically and immunohistochemically labeled synapses in the same lesions. Last, we performed SV2A-PET imaging in a total of 31 PwMS at different stages of the disease process, showing that PET imaging can detect synapse loss in cortical MS lesions in vivo. Moreover, we found that interhemispheric asymmetries in SV2A-PET tracer uptake can be leveraged to uncover further cortical alterations, the volume of which was more than 20-fold larger than the cortical lesion area detected by MRI. The extent of these PET-defined areas of cortical synapse pathology was larger in the progressive stage of the disease and correlated with the disability and cognitive performance of the same individuals. SV2A-PET imaging thus unmasked clinically relevant cortical pathology in MS thereby providing a promising tool to detect and monitor disease progression.